Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Heterologous Prime Boost Vaccination and Ezabenlimab in Pancreatic Ductal Adenocarcinoma
NCT05846516Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- May 2023
- Primary completion
- Mar 2027
- Modality
- Viral Vectors, Oncolytic Viruses, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 1, randomised, open-label trial of VSV-GP154, ATP150, ATP152 and ATP162 in pancreatic ductal adenocarcinoma (PDAC) (4 cohorts), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-Limiting Toxicity at 35 days and Disease-Free Survival at 24 months. Started May 2023; status: active, not recruiting.
02
Drugs
VSV-GP154ATP150ATP152ATP162
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05846516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846516.